APSR2026-889

 
Late-Breaking
Submitted
Poster Presentation
 
AP14-079
P98
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1221194-46904-ASPR AP14-079_432724.pdf
Format: PDF Only
08. Lung Cancer
6

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Nor Syamimi Mohd Isa * Hospital Sultan Idris Shah, Serdang Respiratory Department Selangor Malaysia
Nor Adli Abd Razak - Hospital Pulau Pinang Respiratory Department Pulau Pinang Malaysia
Shu Juen Chong - Hospital Pulau Pinang Intensive Care Unit Pulau Pinang Malaysia
Lalitha Pereirasamy - Hospital Pulau Pinang Respiratory Department Pulau Pinang Malaysia
Irfhan Ali Hyder Ali - Hospital Pulau Pinang Respiratory Department Pulau Pinang Malaysia
Ying Ying Sum - Hospital Pulau Pinang Oncology and Radiotherapy Pulau Pinang Malaysia
 
 
 
 
 
 
 
 
 
Presenting Author Details
Nor Syamimi
Mohd Isa
ndaloose@yahoo.com
+60102336325
31-40
Malaysia
Case Report
From Ventilator to Recovery: Rapid Response to Crizotinib in ROS1 Lung Cancer
Maximum 25 words
Abstract Content
 
 
 
 
Persistent upper lobe consolidation in tuberculosis endemic regions often leads to empirical treatment for smear-negative tuberculosis. However, pneumonic-type lung adenocarcinoma may closely mimic infection and result in delayed diagnosis. Early recognition is crucial as targeted therapy may produce rapid and dramatic responses.
A 58-year-old never-smoker male presented with progressive respiratory failure requiring mechanical ventilation. CT thorax demonstrated persistent right upper lobe consolidation with air bronchograms suggestive of infective aetiology. Despite negative microbiological investigations, empirical anti-tuberculosis therapy was initiated. After 6 weeks, there was no clinical or radiological improvement. Further evaluation with lung biopsy confirmed adenocarcinoma. Comprehensive molecular profiling using next-generation sequencing identified ROS1 gene rearrangement. Crizotinib was subsequently initiated, resulting in rapid clinical improvement. Repeat chest radiography within one week demonstrated marked resolution of the right upper lobe consolidation. The patient was successfully extubated 10 days after initiation of targeted therapy.
ROS1 rearrangements occur in approximately 1–2% of non-small cell lung cancers and are typically seen in never-smokers. Pneumonic-type presentation is uncommon and represents an important diagnostic pitfall, particularly in TB endemic settings. Failure of presumed infection to respond to therapy should prompt early tissue diagnosis and molecular testing. The dramatic response observed highlights the effectiveness of ROS1-targeted therapy even in critically ill patients. ROS1-positive lung adenocarcinoma may masquerade as smear-negative tuberculosis. Early biopsy and molecular testing remain essential in non-resolving consolidation as timely targeted therapy may rapidly reverse respiratory failure and improve outcomes.
 
 
No
Yes
https://storage.unitedwebnetwork.com/files/1285/1221194-37089-CXRpre_381943.jpeg
JPG or JPEG or PNG format ONLY
Lung Cancer, ROS-1, Crizotinib
maximum 3 keywords and no abbreviations, separated by commas
 
235